Puma Biotechnology, Inc. (PBYI) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Zevra Therapeutics, Inc.

Puma Biotechnology, Inc.

Alimera Sciences, Inc.

Applied Therapeutics, Inc.

OptiNose, Inc.

Atara Biotherapeutics, Inc.

Karyopharm Therapeutics, Inc.

Adverum Biotechnologies, Inc.

PDS Biotechnology Corp.

Actinium Pharmaceuticals, Inc.

ESSA Pharma, Inc.

Why is Puma Biotechnology, Inc. ?

Company has a low Debt to Equity ratio (avg) at times

Flat results in Jun 25

NET PROFIT(Q) At USD 5.86 MM has Fallen at -38.48%
NET SALES(Q) At USD 52.44 MM has Fallen at -9.87%
PRE-TAX PROFIT(Q) At USD 6.17 MM has Fallen at -22.85%

With ROE of 39.20%, it has a attractive valuation with a 1.90 Price to Book Value

Over the past year, while the stock has generated a return of 63.91%, its profits have risen by 138.2% ; the PEG ratio of the company is 0

High Institutional Holdings at 83.36%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Their stake has increased by 2.62% over the previous quarter.

Market Beating Performance

The stock has generated a return of 63.91% in the last 1 year, much higher than market (S&P 500) returns of 12.33%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Puma Biotechnology, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Puma Biotechnology, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Puma Biotechnology, Inc.

61.77%

0.55

75.93%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-0.25%

EBIT Growth (5y)

28.63%

EBIT to Interest (avg)

1.37

Debt to EBITDA (avg)

0.17

Net Debt to Equity (avg)

-0.32

Sales to Capital Employed (avg)

1.56

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

83.36%

ROCE (avg)

111.58%

ROE (avg)

32.87%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.90

EV to EBIT

4.11

EV to EBITDA

3.15

EV to Capital Employed

2.33

EV to Sales

0.66

PEG Ratio

0.04

Dividend Yield

ROCE (Latest)

56.73%

ROE (Latest)

39.20%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company

NET PROFIT(HY)

At USD 8.83 MM has Grown at 194.49%

OPERATING CASH FLOW(Y)

Highest at USD 44.34 MM

ROCE(HY)

Highest at 63.24%

DEBT-EQUITY RATIO (HY)

Lowest at -46.68 %

RAW MATERIAL COST(Y)

Fallen by 1.07% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 8.81 times

-4What is not working for the Company

NET PROFIT(Q)

At USD 5.86 MM has Fallen at -38.48%

NET SALES(Q)

At USD 52.44 MM has Fallen at -9.87%

PRE-TAX PROFIT(Q)

At USD 6.17 MM has Fallen at -22.85%

Here's what is working for Puma Biotechnology, Inc.

Operating Cash Flow

Highest at USD 44.34 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Debt-Equity Ratio

Lowest at -46.68 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 8.81 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by 1.07% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Puma Biotechnology, Inc.

Net Profit

At USD 5.86 MM has Fallen at -38.48%

over average net sales of the previous four periods of USD 9.52 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Net Sales

At USD 52.44 MM has Fallen at -9.87%

over average net sales of the previous four periods of USD 58.18 MM

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Pre-Tax Profit

At USD 6.17 MM has Fallen at -22.85%

over average net sales of the previous four periods of USD 7.99 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)